Chang-Ming Charlie Ma
Director, Vice Chairman, Professor
Fox Chase Cancer Center
United States
Advertisement
x
Advertisement
x
Director, Vice Chairman, Professor
Fox Chase Cancer Center
United States
Professor
Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences
China
Associate Professor
University of North Carolina at Chapel Hill
United States
Head
al Bairouni University Hospital and the institute of bio-technology
Syria
Associate Research Scientist
Rumbaugh Goodwin Institute for Cancer Research Nova Southeastern University
United States
Cancer Research Scientist
Technical Writer / Science Consultant
Switzerland
Assistant Professor
University of Athens Medical School, Eginition Hospital
Greece
Lecturer
Nuclear Medicine Consultant at Children's Cancer Hospital
Egypt
Postdoctoral Research Associate
University of Nebraska Medical Center
United States
Published : 03rd June 2022
Authors : Huan Liu1, Chenyang Shen2, Peter Klages2, Kevin Albuquerque2, Chang M Ma1*, Xun Jia2*
Citation : Chang-Ming Ma, Xun Jia, et al. (2022). Interactive Treatment Planning in High Dose-Rate Brachytherapy for Gynecological Cancer. Mathews J Cancer Sci. 7(2):31.
Published : 30th January 2022
Authors : Yanjun Zhang*#, Canliang Yuan*, Dequan Yu
Citation : Zhang Y, et al. (2022). Is Anaplastic Oligodendroglioma Prone to Extracranial Metastasis? A Case Report and Review of Literature. Mathews J Cancer Sci. 7(1):30.
Published : 30th December 2021
Author : C-M Charlie Ma
Citation : Ma C-M. (2021). On the Definition of Sievert and Its SI Unit. Mathews J Cancer Sci. 6(1):29.
Published : 21st December 2021
Authors : X Tong*, FS Luo, GR Yang, DP Wang, X Song, Y Chen, S Wu, N Zhang, QQ Xu, T Zhang, and J Li
Citation : Tong X. (2021). A Clinical Study on Pulsed Low Dose Rate Radiation Therapy for Recurrent Cancers. Mathews J Cancer Sci. 6(1):28.
Published : 21st May 2021
Author : Lili Chen
Citation : Chen L. (2021). Clinical Applications of Pulsed LowDose-Rate Radiation Therapy. Mathews J Cancer Sci. (6)1:27.
Published : 08th October 2020
Authors : Maher Salamoon¹, Mehdi Balti², Bertrand Farnault³, Maher Saifo4, Ali Mahmoud5, Ahmad Khatib6, Manal Daghlawi7, Taisir Husein8, Mazen Kenj9, and Khaled Ghanem10
Citation : Salamoon M. (2020). The Role of Temozolomide-Irinotecan in Doxorubicin-Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?. Mathews J Cancer Sci. (5)1: 21.
Subscribe to our RSS feed, be in touch with our articles, news, videos, reebies.
© 2015 Mathews Open Access Journals. All Rights Reserved.
Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at Mathewsopenaccess.com